Strange Bedfellows: Generics Firms Join Big Pharma In Opposing US Price Negotiation Legislation
Concerns that Medicare drug price negotiation provisions in the Build Back Better legislation would upend the US generic and biosimilar industries might resonate with legislators more than complaints from branded drug companies.
You may also be interested in...
The US Association for Accessible Medicines has panned the Biden administration’s Build Back Better Act, which it says threatens patient access to affordable drugs in its current form.
The legislation would also establish new manufacturer discounts in Medicare Part D as part of a redesign of the benefit that includes a cap on beneficiary out-of-pocket spending. Negotiations are still fluid on the overall legislative package, however, and things could change.
Medicare Price Negotiation Lite? Congress Targets Post-Exclusivity Drugs, Preserves Launch Price Discretion
Legislative deal on drug pricing reform includes a version of US government price negotiation for a subset of Medicare drugs. Only 10 will be selected for negotiation the first year but some analysts believe as many as 100 could be subject to negotiation by 2030.